



SCHOOL OF PUBLIC HEALTH

CENTER FOR VALUE-BASED INSURANCE DESIGN

UNIVERSITY OF MICHIGAN

# Value-Based Insurance Design

**A. Mark Fendrick, MD**

**University of Michigan Center for  
Value-Based Insurance Design**

**[www.vbidcenter.org](http://www.vbidcenter.org)**

**amfen@umich.edu**

**@um\_vbid**



# Improving Care and Bending the Cost Curve

- **The past several decades have produced remarkable medical innovations resulting in impressive reductions in morbidity and mortality**
- **Regardless of these advances, cost growth remains the principle focus of health reform discussions**
- **Despite unequivocal evidence of clinical benefit, Americans systematically underuse high-value services across the entire spectrum of clinical care**
- **Attention should turn from *how much* to *how well* we spend our health care dollars**

# Impact of Cost-Sharing on Health Care Utilization

- **Ideally, consumer cost-sharing levels would be set to encourage the clinically appropriate use of health care services**
- **The archaic “one-size-fits-all” approach to consumer cost-sharing fails to acknowledge the differences in clinical value among medical interventions**
- **A growing body of evidence concludes that increases in cost-sharing leads beneficiaries to reduce the use of essential care, which in some cases, leads to greater overall costs**

# Inspiration

**“I can’t believe you had to spend a million dollars to show that if you make people pay more for something, they will buy less of it.”**

**Barbara Fendrick (my mother)**

# Impact of Cost-Sharing on Health Care Disparities

## Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care


*Michael Chernew, PhD<sup>1</sup> Teresa B. Gibson, PhD<sup>2</sup> Kristina Yu-Isenberg, PhD, RPh<sup>3</sup>  
Michael C. Sokol, MD, MS<sup>4</sup> Allison B. Rosen, MD, ScD<sup>5</sup>, and A. Mark Fendrick, MD<sup>5</sup>*

<sup>1</sup>Department of Health Care Policy, Harvard Medical School, Boston, MA, USA; <sup>2</sup>Thomson Healthcare, Ann Arbor, MI, USA; <sup>3</sup>Managed Markets Division, GlaxoSmithKline, Research Triangle Park, NC, USA; <sup>4</sup>Managed Markets Division, GlaxoSmithKline, Montvale, NJ, USA; <sup>5</sup>Departments of Internal Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Ann Arbor, MI, USA.

- **Rising copayments may worsen disparities and adversely affect health, particularly among patients living in low-income areas.**


# A New Approach: Clinical Nuance

## 1. Services differ in clinical benefit produced




## 2. Clinical benefits from a specific service depend on:

Who  
receives it



Who  
provides it



Where  
it's provided



# Value-Based Insurance Design

- **Sets consumer cost-sharing level on clinical benefit – not acquisition price – of the service**
  - Reduce or eliminate financial barriers to high-value clinical services and providers
- **Successfully implemented by hundreds of public and private payers**



# Evidence for Value-Based Insurance Design: Improving Adherence Without Increasing Costs

- Improved adherence
- Lower consumer costs
- No significant increase in total spending
- Reduced disparities

**EXHIBIT 1**  
Descriptions Of Value-Based Insurance Design (VBID) Policies For Prescription Drugs

Policy (year)	Study authors	Drug class targeted	Pre-VBID plan design	Copay description	Study patients	Outcomes
CVS Caremark (2007)	Chang et al. (Note 8 in text)	Antidiabetics	3 tiers	Copay reductions for tier 1 and tier 2	20,173 beneficiaries from 3 plans	Adherence, cost
Marriott (2005)	Chernew et al. (Notes 6 and 9 in text)	Antidiabetics, ACE inhibitors/ARBs, beta-blockers, statins, steroids	3 tiers	Eliminated for tier 1, tier 2 reduced to \$12.50, tier 3 reduced to \$22.50	37,867 employees and dependents	Adherence, cost
Pitney Bowes (2007)	Choudhry et al. (Notes 10 and 11 in text) Choudhry et al. (Notes 10 and 11 in text)	Statins Clopidogrel	3 tiers 3 tiers	Eliminated for all statins	2,051 beneficiaries with diabetes on statins 779 beneficiaries on clopidogrel	Adherence, cost
Novartis (2005)	Gibson et al. (Note 15 in text), Kelly et al. (Note 20 in text)	Antidiabetics, antihypertensives, bronchodilators	20% coinsurance for retail scripts, 10% coinsurance for mail-order scripts	10% coinsurance for retail scripts, 7.5% coinsurance for mail-order prescriptions	25,784 employee beneficiaries (Gibson et al.) 9,624 employee beneficiaries (Kelly et al.)	Adherence, payment use, Adherence, payment
Florida Health Care Coalition (2006)	Gibson et al. (Note 14 in text)	Antidiabetics	10-35% coinsurance 10-35% coinsurance	10% coinsurance	1,876 employee beneficiaries (Gibson et al.) 328 employee beneficiaries	Adherence, payment, Adherence, payment
Blue Cross Blue Shield of North Carolina (2008)	Maciejewski et al. (Note 16 in text), Farley et al. (Note 12 in text)	Antidiabetics, antihypertensives, cholesterol-lowering medications	3 tiers	10% coinsurance with disease management	747,400 beneficiaries of participating employers	Adherence, cost
State of Colorado (2006)	Nair et al. (Note 17 in text)	Antidiabetics	3 tiers	Eliminated for tier 1 for program participants, reduced for tiers 2 and 3 for all beneficiaries	589 state workers	Adherence, utilization
Blue Cross Blue	Rodin et al. (Note 18)	Antidiabetics,	3 tiers	All drugs and testing supplies reduced to tier 1 Eliminated for tier 1,	4,654 beneficiaries	Adherence,



# Emerging Best Practices in V-BID Implementation

## A 2014 *Health Affairs* evaluation of 76 V-BID plans reported that programs that:

- were more generous
- targeted high-risk individuals
- offered wellness programs
- avoided disease management
- used mail-order prescriptions

had greater impact on adherence than plans without these features

Choudhry. N. *Health Affairs*. 2014;33(3).

### WEB FIRST

By Niteesh K. Choudhry, Michael A. Fischer, Benjamin F. Smith, Gregory Brill, Charmaine Girdi, Olga S. Matlin, Troyen A. Brennan, Jerry Avorn, and William H. Shrank

## Five Features Of Value-Based Insurance Design Plans Were Associated With Higher Rates Of Medication Adherence

**ABSTRACT** Value-based insurance design (VBID) plans selectively lower cost sharing to increase medication adherence. Existing plans have been structured in a variety of ways, and these variations could influence the effectiveness of VBID plans. We evaluated seventy-six plans introduced by a large pharmacy benefit manager during 2007–10. We found that after we adjusted for the other features and baseline trends, VBID plans that were more generous, targeted high-risk patients, offered wellness programs, did not offer disease management programs, and made the benefit available only for medication ordered by mail had a significantly greater impact on adherence than plans without these features. The effects were as large as 4–5 percentage points. These findings can provide guidance for the structure of future VBID plans.

Copayments, coinsurance, deductibles, and other benefit structures are widely used to contain health care spending by encouraging patients to consider the costs of health services before deciding to purchase them. Cost sharing helps address the overconsumption that may result from generous insurance coverage (a type of “moral hazard,” in economic terms).<sup>1</sup> However, it may also lead patients to reduce their use of high-value services.<sup>2</sup> Value-based insurance design (VBID) plans seek to avoid this problem by setting cost-sharing amounts in inverse relationship to the clinical benefit that an intervention offers.<sup>3</sup>

The peer-reviewed literature supports the ability of copay reductions to increase the use of essential medication and improve clinical outcomes.<sup>4–6</sup> As a result, VBID plans have been adopted by many employers and health plans throughout the United States.<sup>10</sup> In addition, the Affordable Care Act calls for the creation of guidelines to facilitate the broader use of VBID plans.

Plans used to treat chronic disease. However, the plans differ in a number of important ways. Some plans target members who meet specific clinical criteria; others reduce copays for all members. Some plans eliminate cost sharing; others only reduce it. Some plans concurrently offer disease management and wellness programs; others do not.

We sought to understand the influence of these and other plan characteristics on how VBID plans affect medication adherence. Based on our results, we identify best practices for the future implementation of VBID plans.

### Study Data And Methods

**SETTING AND PLAN CHARACTERISTICS** We identified VBID plans introduced by a large pharmacy benefit manager, CVS Caremark, on behalf of fifty-nine employer-based plan sponsors between 2007 and 2010. We classified plans according to whether or not they had certain characteristics.

# Multi-Stakeholder Support for V-BID

- **HHS - National Quality Strategy**
- **CBO**
- **SEIU**
- **MedPAC**
- **Brookings Institution**
- **The Commonwealth Fund**
- **NBCH**
- **PCPCC**
- **Partnership for Sustainable Health Care**
- **National Governor's Assoc.**
- **Academy of Actuaries**
- **Bipartisan Policy Center**
- **Kaiser Family Foundation**
- **NBGH**
- **National Coalition on Health Care**
- **Urban Institute**
- **RWJF**
- **IOM – Essential Health Benefits**

# Federal and State Policy Efforts



# ACA Sec. 2713c Regulation: V-BID Definition

**“Value-based insurance designs include the provision of information and incentives for consumers that promote access to and use of higher value providers, treatments, and services.”**

# Sec 2713: Selected Preventive Services be Provided without Cost-Sharing

- **Receiving an A or B rating from the United States Preventive Services Taskforce (USPSTF)**
- **Immunizations recommended by the Advisory Committee on Immunization Practices (ACIP)**
- **Preventive care and screenings supported by the Health Resources and Services Administration (HRSA)**



Over **100 million** Americans have received expanded coverage of preventive services



# V-BID in Medicare

## ***Value-Based Insurance Design Copayment Reduction Act of 2014***

IN THE SENATE OF THE UNITED STATES

Mr. THUNE introduced the following bill; which was read twice and referred  
to the Committee on \_\_\_\_\_

### **A BILL**

To establish a demonstration program requiring the utilization of Value-Based Insurance Design in order to demonstrate that reducing the copayments or coinsurance charged to Medicare beneficiaries for selected high-value prescription medications and clinical services can increase their utilization and ultimately improve clinical outcomes, enhance beneficiary satisfaction, and lower health care expenditures.

## ***The Better Care, Lower Cost Act of 2014***



Sponsored by:

U.S. Sen. Ron Wyden, D-Ore.

U.S. Sen. Johnny Isakson, R-Ga.

U.S. Rep. Erik Paulsen, R-Minn.

U.S. Rep. Peter Welch, D-Vt.

# Institute of Medicine Essential Health Benefits Report

## Recognition of Clinical Nuance

**“The EHB must be affordable, maximize the number of people with insurance, protect the most vulnerable individuals, promote better care, ensure stewardship of limited financial resources by focusing on high value services of proven effectiveness, promote shared responsibility for improving our health, and address the medical concerns of greatest importance to us all.”**


# Value-Based Insurance Design Growing Role in State Health Reform

- **State Employees Benefit Plans**
  - Connecticut
  - Oregon
  - Virginia
  - Minnesota
  - Maine
- **State Exchanges**
  - Maryland
  - California
- **CO-OPs**
- **Medicaid**





# CMS Rules (CMS-2334-F) Enable V-BID in Medicaid



- Plans may vary cost-sharing for drugs, outpatient, inpatient, and emergency department visits
- Plans may target cost-sharing to specific groups of individuals based on clinical information (e.g., diagnosis, risk factors)
- Plans may vary cost-sharing for an outpatient service according to where and by whom the service is provided


# V-BID Prominently Featured in Healthy Michigan Plan

- **Sec 105D(1)(e), plans may waive consumer copayments, “to promote greater access to services that prevent the progression and complications related to chronic diseases.”**
- **Sec 105D(1)(f), assigned to “design and implement a copay structure that encourages the use of high-value services, while discouraging low-value services.”**
- **Sec 105D(5), assigned to “implement a pharmaceutical benefit that utilizes copays at appropriate levels allowable by CMS to encourage the use of high-value, low-cost prescriptions.”**



# Barriers to V-BID in HSA-qualified HDHPs

- IRS guidance documents specifically exclude from the definition of preventive care those services or benefits meant to treat “an existing illness, injury or condition
- Confusion persists what services can and cannot be covered outside of the deductible



# Moving Forward

- The ultimate test of health reform will be whether it improves health and addresses rising costs
- Cost containment efforts should not result in preventable reductions in quality of care
- V-BID should be part of the solution to enhance the efficiency of health care spending



Mullainathan S. When a Co-Pay Gets in the Way of Health. The New York Times. 2013 Aug 10.



# Discussion

[www.vbidcenter.org](http://www.vbidcenter.org)

**@um\_vbid**

**vbidcenter@umich.edu**